Jump to content

User:MBC 01/Center for Translational Molecular Medicine

From Wikipedia, the free encyclopedia

Center for Translational Molecular Medicine ...

Center for Translational Molecular Medicine (CTMM)
Established2006
FocusTranslating science into better healthcare
Chair of the Supervisory BoardFrank de Grave
Budget€302.7 million
Location
High Tech Campus, Eindhoven, The Netherlands
,
The Netherlands
Websitewww.ctmm.nl

The Center for Translational Molecular Medicine (CTMM) is a Dutch research organization that focuses on the development of medical technologies that enable the early diagnosis and personalized treatment of major diseases that cause mortality and diminished quality of life. The areas of disease that its research projects address are cancer, cardiovascular, neurodegenerative, infectious and autoimmune diseases.[1] Founded in 2006 with its headquarters on the High Tech Campus Eindhoven, the CTMM is one of the Netherlands’ Technological Top Institutes (TTIs) and is funded via a public-private partnership between the Dutch government, academic institutions and industrial partners (most of which are Netherlands based). As at January 2012, the CTMM had a total of 112 partners, comprising large industrial companies, small and medium enterprises (SMEs) and academic institutes, including all eight Dutch university medical centers and two technical universities (Eindhoven University of Technology and Delft University of Technology).[2]

The CTMM provides the legal, accounting and project coordination services - for example, calls for proposals and project selection, approval, monitoring and review - to fund eighteen 5-year and three 4-year translational molecular medicine research projects and one IT infrastructure project in the Netherlands.[3] As at January 2012, the total funding allocated to these projects was Euro 302.7 million. The CTMM also provides education and training programs for its members.[3]

Research Projects

[edit]

As at January 2012, the CTMM had 22 ongoing research projects (21 translational molecular medicine research projects and one IT infrastructure project), eighteen of which will run for 5 years and four of which will run for 4 years.[1][4]

Grouped by disease area the projects are:[1]

Disease Area Project Name/Description Acronym
Cancer Personalized chemo-radiation of lung and head and neck cancer Airforce
BioChip diagnostic tests for acute leukemia and multiple myeloma BioChip
Neoadjuvant drug treatment for breast cancer response prediction and response monitoring Breast Care
Cancer Vaccine Tracking -
Decrease colorectal cancer death DeCode
Application of MRI-guided High Intensity Focused Ultrasound (HIFU) to improve cancer chemotherapy with temperature-sensitive targeted nanomedicines HIFU-CHEM
Mammary carcinoma molecular imaging for diagnosis and therapeutics MamMoth
Intra-operative multi-spectral imaging systems for radical tumor resection Musis
Prostate cancer molecular medicine PCMM
Non-invasive treatment of cancer by MRI-guided high-intensity focused ultrasound ablation: volumetric thermal ablation Volta
Cardiovascular Disease Circulating Cells: The natural sensors of plaque and patient destabilization Circulating Cells
Biomarkers to predict cardiac failure, arrhythmias and success of treatment Cohfar
Developing multiple diagnostic technologies to enable the early sensitive detection of neovascularization, and novel tools to stratify an individual patient’s risk of cardiovascular disease Eminence
Innovative coagulation diagnostics Incoag
Assessment of plaque at risk by non-invasive (molecular) imaging and modeling Parisk
Biomarkers for the prediction and early diagnosis of diabetes and diabetes-related cardiovascular complications Predicct
Translational initiative on unique and novel strategies for the management of patients with heart failure Triumph
Neurodegenerative Disease In-vivo molecular diagnostics in Alzheimer's disease Learn
Infection and Immunity Design and use of enhanced T cell antigens and T cell detection technology for human disease AmpVacs
Molecular diagnosis and risk stratification of sepsis Mars
Development of tools and prediction rules to time and select therapy in the treatment of pre-clinical, early and established rheumatoid arthritis: creating enhanced remedy Tracer

The 22nd project is called TraIT (Translational research IT) and aims to develop a sustainable and scalable IT infrastructure in the Netherlands based on proven technology.[5] TraIT will allow researchers in distributed research centers to combine and jointly analyze their data to develop more personalized healthcare in disease areas such as cancer and cardiovascular disease.

Every project is subject to a Midterm Review by the International Scientific Advisory Board, which critically analyzes the extent to which the project has progressed and helps CTMM to identify practical measures to increase commitment, resourcing and efforts during the second half of the project.

Funding

[edit]

How CTMM Obtains Funding

[edit]

In 2007 and 2008, the Dutch government committed Euro 150 million to the newly formed CTMM from the government’s FES fund (Fonds Economische Structuurversterking), which it created using revenues from its Slochteren natural gas field in the North of the Netherlands.[citation needed] The public-private partnership agreement under which CTMM operates requires that this Euro 150 million from the Dutch government is matched by funding from CTMM’s industrial and academic partners, giving the CTMM a total budget of Euro 300 million to spend on translational research.[citation needed] Some projects were awarded additional funding from Dutch charitable organizations, including the Dutch Heart Foundation, Diabetes Research Foundation, Kidney Foundation, Arthritis Foundation and Cancer Society.[1][5]

How CTMM Allocates Funding

[edit]

Project proposals, which are evaluated by CTMM’s independent International Scientific Advisory Committee and approved by CTMM’s Supervisory Board, bring together consortia of industrial and academic partners. The consortium partners collectively agree to match the government funding allocated to the project, in an even split between the industrial and academic groups.[citation needed] Hence for each CTMM project, 50% of the project funding comes from the Dutch government, 25% from the project’s industrial partners and 25% from its academic partners.[3] Depending on their resources, partners can either contribute funding in cash or in-kind (i.e. in the form of goods or services). The funding for each project is spread over the duration of the project and is administered by CTMM.

See also

[edit]

References

[edit]
  1. ^ a b c d CTMM. "CTMM Annual Report 2010". CTMM. Retrieved March 25, 2012. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  2. ^ CTMM. "Partners in the CTMM consortium". CTMM. Retrieved March 25, 2012. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  3. ^ a b c CTMM. Engels "About CTMM". CTMM. Retrieved March 25, 2012. {{cite web}}: Check |url= value (help); Cite has empty unknown parameter: |coauthors= (help)
  4. ^ CTMM. "CTMM Projects - general information". CTMM. Retrieved March 25, 2012. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  5. ^ a b "Sixteen million Euro to accelerate the translation of highly promising medical research into clinical care" (Press release). CTMM. October 3, 2011. {{cite press release}}: line feed character in |title= at position 94 (help)
[edit]